ENTRESTO SPRINKLE Drug Patent Profile
✉ Email this page to a colleague
When do Entresto Sprinkle patents expire, and when can generic versions of Entresto Sprinkle launch?
Entresto Sprinkle is a drug marketed by Novartis and is included in one NDA. There are four patents protecting this drug.
This drug has one hundred and twenty-seven patent family members in forty countries.
The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. There are eleven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the sacubitril; valsartan profile page.
DrugPatentWatch® Generic Entry Outlook for Entresto Sprinkle
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be May 27, 2027. This may change due to patent challenges or generic licensing.
There have been thirteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ENTRESTO SPRINKLE?
- What are the global sales for ENTRESTO SPRINKLE?
- What is Average Wholesale Price for ENTRESTO SPRINKLE?
Summary for ENTRESTO SPRINKLE
International Patents: | 127 |
US Patents: | 4 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Formulation / Manufacturing: | see details |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ENTRESTO SPRINKLE |
DailyMed Link: | ENTRESTO SPRINKLE at DailyMed |
![ENTRESTO SPRINKLE drug patent expirations Drug patent expirations by year for ENTRESTO SPRINKLE](/p/graph/s/t/ENTRESTO_SPRINKLE-patent-expirations.png)
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ENTRESTO SPRINKLE
Generic Entry Date for ENTRESTO SPRINKLE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE, PELLETS;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for ENTRESTO SPRINKLE
Drug Class | Angiotensin 2 Receptor Blocker Neprilysin Inhibitor |
Mechanism of Action | Angiotensin 2 Receptor Antagonists Neprilysin Inhibitors |
US Patents and Regulatory Information for ENTRESTO SPRINKLE
ENTRESTO SPRINKLE is protected by four US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ENTRESTO SPRINKLE is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ENTRESTO SPRINKLE
Galenic formulations of organic compounds
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HEART FAILURE WITH ORAL PELLETS
Methods of treatment and pharmaceutical composition
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF HEART FAILURE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | ENTRESTO SPRINKLE | sacubitril; valsartan | CAPSULE, PELLETS;ORAL | 218591-001 | Apr 12, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Novartis | ENTRESTO SPRINKLE | sacubitril; valsartan | CAPSULE, PELLETS;ORAL | 218591-002 | Apr 12, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Novartis | ENTRESTO SPRINKLE | sacubitril; valsartan | CAPSULE, PELLETS;ORAL | 218591-001 | Apr 12, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Novartis | ENTRESTO SPRINKLE | sacubitril; valsartan | CAPSULE, PELLETS;ORAL | 218591-002 | Apr 12, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Novartis | ENTRESTO SPRINKLE | sacubitril; valsartan | CAPSULE, PELLETS;ORAL | 218591-001 | Apr 12, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Novartis | ENTRESTO SPRINKLE | sacubitril; valsartan | CAPSULE, PELLETS;ORAL | 218591-001 | Apr 12, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Novartis | ENTRESTO SPRINKLE | sacubitril; valsartan | CAPSULE, PELLETS;ORAL | 218591-002 | Apr 12, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for ENTRESTO SPRINKLE
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Novartis Europharm Limited | Neparvis | sacubitril, valsartan | EMEA/H/C/004343 Paediatric heart failureNeparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5.1).Adult heart failureNeparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.1). |
Authorised | no | no | no | 2016-05-26 | |
Novartis Europharm Limited | Entresto | sacubitril, valsartan | EMEA/H/C/004062 Paediatric heart failureEntresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction.Adult heart failureEntresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction. |
Authorised | no | no | no | 2015-11-19 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ENTRESTO SPRINKLE
When does loss-of-exclusivity occur for ENTRESTO SPRINKLE?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 7882
Patent: COMPUESTOS DE ACCION DOBLE DE BLOQUEADORES DEL RECEPTOR DE ANGIOTENSINA E INHIBIDORES DE ENDOPEPTIDASA NEUTRA
Estimated Expiration: ⤷ Sign Up
Patent: 6613
Patent: [HEMI-PENTAHIDRATO DE [3-((1S,3R)-1-BIFENIL-4-ILMETIL-3-ETOXI-CARBONIL-1-BUTIL-CARBAMOIL)-PROPIONATO-(S)-3 -METIL-2 -(PENTANOIL-{2 -(TETRAZOL-5-ILATO)-BIFENIL-4 -ILMETIL}-AMINO)-BUTIRATO] DE TRISODIO
Estimated Expiration: ⤷ Sign Up
Patent: 6614
Patent: COMPUESTOS ORGÁNICOS
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 06311481
Patent: Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0605921
Patent: compostos orgánicos
Estimated Expiration: ⤷ Sign Up
Patent: 2013025375
Patent: compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 90511
Patent: COMBINAISON PHARMACEUTIQUES D'UN ANTAGONISTE DE RECEPTEUR D'ANGIOTENSINE ET D'UN INHIBITEUR DE NEP (PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR)
Estimated Expiration: ⤷ Sign Up
China
Patent: 1098689
Patent: Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor
Estimated Expiration: ⤷ Sign Up
Patent: 2702119
Patent: Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0140274
Estimated Expiration: ⤷ Sign Up
Patent: 0201605
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 15004
Estimated Expiration: ⤷ Sign Up
Patent: 23531
Estimated Expiration: ⤷ Sign Up
Patent: 16014
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 48158
Estimated Expiration: ⤷ Sign Up
Patent: 40828
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 14019136
Patent: COMBINACIONES FARMACÉUTICAS DE UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA Y UN INHIBIDOR DE ENDOPEPTIDASA NEUTRA (NEP)
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 48158
Patent: COMBINAISON PHARMACEUTIQUES D'UN ANTAGONISTE DE RECEPTEUR D'ANGIOTENSINE ET D'UN INHIBITEUR DE NEP (PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR)
Estimated Expiration: ⤷ Sign Up
Patent: 40828
Patent: Combinaisons pharmaceutiques d'un antagoniste de récepteur de l'angiotensine et inhibiteurs de nep (PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR)
Estimated Expiration: ⤷ Sign Up
Patent: 85833
Patent: COMPOSÉ COMPRENANT UN ARB ET UN NEPI (COMPOUND COMPRISING AN ARB AND A NEPI)
Estimated Expiration: ⤷ Sign Up
France
Patent: C0018
Estimated Expiration: ⤷ Sign Up
Patent: C1000
Estimated Expiration: ⤷ Sign Up
Guatemala
Patent: 0700055
Patent: COMBINACIONES FARMACEUTICAS DE UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA Y UN INHIBIDOR DE ENDOPEPTIDASA NEUTRAL (NEP).
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 21371
Patent: PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR
Estimated Expiration: ⤷ Sign Up
Patent: 75465
Patent: 血管緊張素受體拮抗劑和 抑制劑的藥物組合產品 (PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR NEP)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 50870
Estimated Expiration: ⤷ Sign Up
Patent: 600025
Estimated Expiration: ⤷ Sign Up
Patent: 100003
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 4027
Patent: תרכובת טריסודיום [3-((1s, 3r)-1-ביפניל-4-ילמתיל-3-אתוקסיקרבוניל-1-בוטילקרבמויל)פרופיונאט-(s)-'3-מתיל-'2-(פנטהנויל{" 2-(טטרזול-5-ילאט)ביפניל-'4-ילמתיל}אמינו)בוטיראט] המיפנטההידראט, תכשירים רוקחיים שלה, שיטה להכנתה ושימוש בה להכנת תרופות (Compound trisodium [3-((1s,3r)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(s)-3’-methyl-2’-(pentanoyl{2’’-(tetrazol-5-ylate)biphenyl-4’-ylmethyl}amino)butyrate] hemipentahydrate, its pharmaceutical compositions, method for its preparation and use thereof in the preparation of medicaments)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 24754
Estimated Expiration: ⤷ Sign Up
Patent: 08542447
Estimated Expiration: ⤷ Sign Up
Patent: 11252013
Patent: PHARMACEUTICAL COMBINATION OF ANGIOTENSIN RECEPTOR ANTAGONIST AND NEP INHIBITOR
Estimated Expiration: ⤷ Sign Up
Patent: 15098485
Patent: アンギオテンシン受容体遮断剤とNEP阻害剤との医薬組成物 (PHARMACEUTICAL COMBINATIONS OF ANGIOTENSIN RECEPTOR ANTAGONIST AND NEP INHIBITOR)
Estimated Expiration: ⤷ Sign Up
Jordan
Patent: 92
Patent: تركيبات صيدلانية من مضاد مستقبل أنجيوتنسين ومثبط NEP (PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR)
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 948158
Estimated Expiration: ⤷ Sign Up
Patent: 2021502
Estimated Expiration: ⤷ Sign Up
Patent: 40828
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 5462
Patent: PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 07008075
Patent: COMBINACIONES FARMACEUTICAS DE UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA Y UN INHIBIDOR DE ENDOPEPTIDASA NEUTRAL (NEP). (PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR.)
Estimated Expiration: ⤷ Sign Up
Morocco
Patent: 128
Patent: COMBINAISONS PHARMACEUTIQUES D'UN ANTAGONISTE DE RECEPTUER D'ANGIOTENSINE ET D'UN INHIBITEUR DE NEP
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 4006
Patent: Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor
Estimated Expiration: ⤷ Sign Up
Patent: 0626
Patent: Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 7288
Estimated Expiration: ⤷ Sign Up
Patent: 0315
Estimated Expiration: ⤷ Sign Up
Patent: 16008
Estimated Expiration: ⤷ Sign Up
Patent: 073396
Estimated Expiration: ⤷ Sign Up
Patent: 151656
Patent: Farmasøytiske kombinasjoner av en angiotensinreseptorantagonist og en nepinhibitor
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 070803
Patent: COMBINACION FARMACEUTICA DE UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA Y UN INHIBIDOR DE ENDOPEPTIDASA NEUTRA
Estimated Expiration: ⤷ Sign Up
Patent: 190374
Patent: COMBINACION FARMACEUTICA DE UN ANTAGONISTA DEL RECEPTOR DE ANGIOTENSINA Y UN INHIBIDOR DE ENDOPEPTIDASA NEUTRA
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 48158
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 48158
Estimated Expiration: ⤷ Sign Up
Patent: 40828
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 59809
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ АНТАГОНИСТА РЕЦЕПТОРА АНГИОТЕНЗИНА И ИНГИБИТОРА NEP (PHARMACEUTICAL COMBINATIONS OF ANGIOTENSINE RECEPTOR ANTAGONIST AND NEP INHIBITOR)
Estimated Expiration: ⤷ Sign Up
Patent: 03668
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ АНТАГОНИСТА РЕЦЕПТОРА АНГИОТЕНЗИНА И ИНГИБИТОРА NEP (PHARMACEUTICAL COMBINATIONS OF ANGIOTENSIN RECEPTOR ANTAGONIST AND NEP INHIBITOR)
Estimated Expiration: ⤷ Sign Up
Patent: 07123671
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ АНТАГОНИСТА РЕЦЕПТОРА АНГИОИЕНЗИНА И ИНГИБИТОРА NEP
Estimated Expiration: ⤷ Sign Up
Patent: 12107219
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ АНТАГОНИСТА РЕЦЕПТОРА АНГИОТЕНЗИНА И ИНГИБИТОРА NEP
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 201402055Y
Patent: PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 48158
Estimated Expiration: ⤷ Sign Up
Patent: 40828
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 0704717
Patent: Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1432821
Estimated Expiration: ⤷ Sign Up
Patent: 1549318
Estimated Expiration: ⤷ Sign Up
Patent: 080075055
Patent: PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR
Estimated Expiration: ⤷ Sign Up
Patent: 130116381
Patent: PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 49765
Estimated Expiration: ⤷ Sign Up
Patent: 23749
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 18348
Estimated Expiration: ⤷ Sign Up
Patent: 54504
Estimated Expiration: ⤷ Sign Up
Patent: 0803834
Patent: Organic compounds
Estimated Expiration: ⤷ Sign Up
Patent: 1402111
Patent: Dual-acting compound, pharmaceutical composition containing it, process for its preparation and use thereof
Estimated Expiration: ⤷ Sign Up
Tunisia
Patent: 07264
Patent: ORGANIC COMPOUNDS
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering ENTRESTO SPRINKLE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2008542447 | ⤷ Sign Up | |
Mexico | PA04006917 | COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN INHIBIDORES DE VALSARTAN Y ENDOPEPTIDASA NEUTRA. (PHARMACEUTICAL COMPOSITIONS COMPRISING VALSARTAN AND NEP INHIBITORS.) | ⤷ Sign Up |
Norway | 2016008 | ⤷ Sign Up | |
Russian Federation | 2012107219 | ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ АНТАГОНИСТА РЕЦЕПТОРА АНГИОТЕНЗИНА И ИНГИБИТОРА NEP | ⤷ Sign Up |
Israel | 184027 | תרכובת טריסודיום [3-((1s, 3r)-1-ביפניל-4-ילמתיל-3-אתוקסיקרבוניל-1-בוטילקרבמויל)פרופיונאט-(s)-'3-מתיל-'2-(פנטהנויל{" 2-(טטרזול-5-ילאט)ביפניל-'4-ילמתיל}אמינו)בוטיראט] המיפנטההידראט, תכשירים רוקחיים שלה, שיטה להכנתה ושימוש בה להכנת תרופות (Compound trisodium [3-((1s,3r)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(s)-3’-methyl-2’-(pentanoyl{2’’-(tetrazol-5-ylate)biphenyl-4’-ylmethyl}amino)butyrate] hemipentahydrate, its pharmaceutical compositions, method for its preparation and use thereof in the preparation of medicaments) | ⤷ Sign Up |
Canada | 2472399 | COMPOSITIONS PHARMACEUTIQUES A BASE DE VALSARTAN ET D'INHIBITEURS NEP (PHARMACEUTICAL COMPOSITIONS COMPRISING VALSARTAN AND NEP INHIBITORS) | ⤷ Sign Up |
Canada | 2590511 | COMBINAISON PHARMACEUTIQUES D'UN ANTAGONISTE DE RECEPTEUR D'ANGIOTENSINE ET D'UN INHIBITEUR DE NEP (PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ENTRESTO SPRINKLE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2340828 | PA2021502,C2340828 | Lithuania | ⤷ Sign Up | PRODUCT NAME: SAKUBITRILAS/VALSARTANAS, KAIP SAKUBITRILO VALSARTANO NATRIO DRUSKOS KOMPLEKSAS, T.Y. (((S)-N-VALERIL-N-((2'-(1H-TETRAZOL-5-IL)-BIFENIL-4-IL)-METIL)-VALINAS)((2R,4S)-5-BIFENIL-4-IL-4-(3-KARBOKSI-PROPIONILAMINO)-2-METIL-PENTANO RUGSTIES ETILO ESTERIS)NA3 - X H2O, KUR X YRA 0 - 3; REGISTRATION NO/DATE: EU/1/15/1058 20151119 |
2340828 | LUC00195 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: SACUBITRIL ET VALSARTAN, SOUS FORME DE COMPLEXE DE SEL DE SODIUM SACUBITRIL VALSARTAN, C'EST-A-DIRE (((S)-N-VALERYL-N-((2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL)-METHYL)-VALINE) ((2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-ESTER ETHYLIQUE D'ACIDE PENTANOIQUE))NA3 X H2O, DANS LEQUEL X EST 0 A 3; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123 |
1948158 | 132016000051118 | Italy | ⤷ Sign Up | PRODUCT NAME: SACUBITRIL/VALSARTAN, COME SACUBITRIL VALSARTAN COMPLESSO DI SALE SODICO (TRISODIO (3-((1S,3R)-1-BIFENIL-4-ILMETIL-3-ETOSSICARBONIL-1-BUTILCARBAMMOIL)PROPIONATO-(S)-3'-METIL-2'-(PENTANOIL(2"-(TETRAZOL-5-ILATO)BIFENIL-4'-ILMETIL)AMMINO)BUTIRRATO) EMIPENTAIDRATO)(ENTRESTO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1058, 20151123 |
1467728 | 132016000051059 | Italy | ⤷ Sign Up | PRODUCT NAME: SACUBITRIL/VALSARTAN, INCLUSI LORO SALI FARMACEUTICAMENTE ACCETTABILI(ENTRESTO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1058 - C(2015)8288, 20151123 |
1467728 | CA 2016 00022 | Denmark | ⤷ Sign Up | PRODUCT NAME: SACUBITRIL/VALSARTAN, HERUNDER FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/15/1058 (C(2015)8288) 20151123 |
2340828 | PA2021502 | Lithuania | ⤷ Sign Up | PRODUCT NAME: SAKUBITRILAS/VALSARTANAS, KAIP SAKUBITRILO VALSARTANO NATRIO DRUSKOS KOMPLEKSAS, T.Y. (((S)-N-VALERIL-N-((2'-(1H-TETRAZOL-5-IL)-BIFENIL-4-IL)-METIL)-VALINAS)((2R,4S)-5-BIFENIL-4-IL-4-(3-KARBOKSI-PROPIONILAMINO)-2-METIL-PENTANO RUGSTIES ETILO ESTERIS)NA3; REGISTRATION NO/DATE: EU/1/15/1058 20151119 |
1467728 | 19/2016 | Austria | ⤷ Sign Up | PRODUCT NAME: SACUBITRIL/VALSARTAN, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/15/1058 20151119 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |